Overall, this study provides critical insights into the pathways affected in tumor-infiltrating myeloid cells during the progression of CRC and their potential contribution to disease progression, and identifies a CD33+ gene signature which predicts poor disease-specific survival in CRC patients. The gene discussed is CD33; the disease is neoplasm.